Cancer Treatment Research

Active

Assistance listing
93.395
Agency
Grant awards
18,287 $28,262,839,486 in federal obligations

Program facts

Assistance types
  • Project Grant
  • Cooperative Agreement
  • Block Grant
Treasury account
  • 75-0849-0-1-550
More information

Program details come from SAM.gov Assistance Listings. Updated . Grant award figures come from USAspending.gov.

About this program

The Department of Health and Human Services National Institutes of Health funds cancer treatment research development and evaluation through CFDA 93.395, with the most recent grant award disbursed on September 3, 2026. The program supports discovery, development, and clinical testing of all therapeutic modalities—surgery, radiotherapy, chemotherapy, biological therapy including molecularly targeted therapies, stem cell and bone marrow transplantation, image-guided therapies, and supportive care methods that enhance primary treatment. Research spans fundamental and applied laboratory and clinical investigation to develop means to cure cancer patients and control disease in those not cured.

Grant awards remain highly active, with 391 awards in 2026 following 486 in 2024, 504 in 2023, and 515 in 2022—representing consistent annual funding around 400–500 awards. The program has sustained operations for over fifty years, with initial awards dating to October 1975. Combined federal dollars obligated total $28.26 billion across 18,287 awards; non-federal cost-share adds $1.36 billion for a combined total of $29.62 billion. The portfolio is dominated by the National Cancer Institute, which accounts for 5,502 awards and $20.5 billion in federal dollars—a 72% share of total federal funding. The broader NIH (non-NCI components) accounts for an additional 12,445 awards and $7.28 billion. Assistance-type distribution is heavily weighted toward Project Grants at 86% of the award count (15,734 awards), with Cooperative Agreements at 10% (1,744 awards) and Block Grants at 4% (809 awards).

Representative recent awards exemplify program scope: translation of oncolytic immunotherapy for colorectal cancer ($306,756); CAR-T cell therapy enhancement for diffuse large B-cell lymphoma ($548,528); cuproptosis-based approaches to chemoresistant ovarian cancer ($444,569); development of novel Wnt inhibitors for colorectal cancer through Phase I SBIR ($399,998); and AI-driven multi-omics integration for acute lymphoblastic leukemia categorization ($307,000). Award magnitudes typically range from $300 thousand to $700 thousand for standard R01/R21 projects, with larger Program Project ($2.7 million) and cooperative agreement awards occasionally exceeding $1 million.

Grant opportunities posted recently include the Investigator-Focused Award (Parent R35; PAR-28-037, posted July 30, 2026) to fund investigator programs with scientific freedom and funding stability; Advanced Development of Informatics Technologies for Cancer Research (RFA-CA-28-003, U24 Cooperative Agreement, posted July 28, 2026); and the Radiation Oncology-Biology Integration Network Centers (RFA-CA-27-003, U54 Cooperative Agreement, posted June 2, 2026). SBIR and STTR mechanisms remain active, with multiple small-business focused opportunities carrying due dates through 2029. The program exhibits no recent opportunities with near-term deadlines; most posted opportunities carry due dates of 2027 or later, suggesting opportunity posting activity remains steady but not urgent.

Objective and description

Objective

To develop the means to cure as many cancer patients as possible and to control the disease in those patients who are not cured. Cancer Treatment Research includes the development and evaluation of improved methods of cancer treatment through the su

Description

To develop the means to cure as many cancer patients as possible and to control the disease in those patients who are not cured. Cancer Treatment Research includes the development and evaluation of improved methods of cancer treatment through the support and performance of both fundamental and applied laboratory and clinical research. Research is supported in the discovery, development, and clinical testing of all modes of therapy including: surgery, radiotherapy, chemotherapy, and biological therapy including molecularly targeted therapies, both individually and in combination. In addition, research is carried out in areas of nutritional support, stem cell and bone marrow transplantation, image guided therapies and studies to reduce toxicity of cytotoxic therapies, and other methods of supportive care that may supplement and enhance primary treatment. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to increase private sector commercialization of innovations derived from Federal research and development; to increase small business participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.

Eligibility

Applicant eligibility

The awardee will be a university, college, hospital, public agency, nonprofit research institution, or for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned, and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.

Beneficiary eligibility

Any nonprofit or for-profit organization, company, or institution engaged in biomedical research.

Uses of assistance

Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. SBIR Phase I grants (of approximately 6-months duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I, and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. The SBIR Fast-Track Initiative provides additional assistance to applicants by expediting the decision and award of SBIR Phase II funding for scientifically meritorious applications for projects that have a high potential for commercialization. Fast-Track is a parallel option whereby Phase I and Phase II projects are reviewed concurrently with the aim of reducing or eliminating the funding gap between Phase I and Phase II.

Length and time phasing of assistance

Grants and cooperative agreements: Average 3 to 4 years, maximum of 5 years. Renewals may be awarded for additional periods of up to 5 years based on competitive peer review. Funds are provided through Monthly Demand Payment System or an Electronic Transfer System. SBIR: Normally, Phase I awards are for 6 months; normally, Phase II awards are for 2 years. STTR: Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2 years.

How to apply

Criteria for selecting proposals

The major elements in evaluating applications include assessments of: (1) The scientific merit and general significance of the proposed study and its objectives; (2) the technical adequacy of the experimental design and approach; (3) the competency of the proposed investigator or group to successfully pursue the project; (4) the adequacy of the available and proposed facilities and resources; (5) the necessity of the budget components requested in relation to the proposed project; and (6) the relevance and importance to announced program objectives. The following criteria will be used in considering the scientific and technical merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical merit of the proposed approach; (2) the qualifications of the proposed principal investigator, supporting staff, and consultants; (3) the technological innovation of the proposed research; (4) the potential of the proposed research for commercial application; (5) the appropriateness of the budget requested; (6) the adequacy and suitability of the facilities and research environment; and (7) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment. Phase II grant applications will be reviewed based upon the following criteria: (1) The degree to which the Phase I objectives were met and feasibility demonstrated; (2) the scientific and technical merit of the proposed approach for achieving the Phase II objectives; (3) the qualifications of the proposed principal investigator, supporting staff, and consultants; (4) the technological innovation, originality, or societal importance of the proposed research; (5) the potential of the proposed research for commercial application; (6) the reasonableness of the budget requested for the work proposed; (7) the adequacy and suitability of the facilities and research environment; and (8) where applicable, the adequacy of assurances detailing the proposed means for (a) safeguarding human or animal subjects, and/or (b) protecting against or minimizing any adverse effect on the environment.

Award procedure

Grant applications are evaluated by scientific authorities for scientific and technical merit. Applications must also be reviewed by the National Cancer Advisory Board. All competitive applications compete for available funds on the basis of scientific and technical merit, program relevance, and program balance, consistent with NCI and NIH priorities and strategic plans. Initial award provides funds for the first budget period (usually 12 months) and Notice of Grant Award (Form PHS 1533-2) indicates support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any. All accepted SBIR/STTR applications are evaluated for scientific and technical merit by an appropriate scientific peer review panel and if they are recommended for further consideration, by a national advisory council or board. All applications receiving a priority score compete for available SBIR/STTR set-aside funds on the basis of scientific and technical merit and commercial potential of the proposed research, program relevance, and program balance among the areas of research.

Time to approval or disapproval

Approximately 10 months. SBIR Applications: About 7-1/2 months.

Renewals

Applications submitted for renewal are reviewed and selected for funding on a competitive basis.

Appeals

A principal investigator (P.I.) may question the substantive or procedural aspects of the review of his/her application with the staff of the Institute. A description of the NIH Peer Review Appeal procedures is available on the NIH home page http://grants.nih.gov/grants/guide/notice-files/not97-232.html

Grant opportunities

Opportunity Status Posted Applications due
Investigator-Focused Award (Parent R35) PAR-28-037 Forecasted —
Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-28-003 Forecasted —
Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required) RFA-CA-27-003 Forecasted —
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) PAR-27-089 Forecasted —
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) PAR-27-088 Forecasted —
Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) PAR-27-009 Forecasted —
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) RFA-CA-26-010 Forecasted —
Single source: Childhood Cancer Survivor Study (U24 Clinical Trial Not Allowed) RFA-CA-26-011 Past —
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed) PAR-26-129 Past —
Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) PAR-26-152 Forecasted —
NIH Research Program Projects (Parent P01 Clinical Trial Optional) PA-27-061 Open
NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional) PA-26-002 Open
Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) (P30 Clinical Trial Not Allowed) PAR-28-090 Open
INCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed) RFA-OD-27-003 Open
INCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed) RFA-OD-27-004 Open
INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required) RFA-OD-27-005 Open
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) RFA-CA-27-005 Open
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) PAR-27-072 Open
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required) PAR-28-022 Open
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-26-001 Open
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-27-021 Closed
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) RFA-CA-27-020 Closed
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) RFA-CA-27-019 Open
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) PA-27-100 Open
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) PA-27-102 Open
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) PA-27-101 Open
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required) PAR-27-078 Open
Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) FOR-CA-25-086 Past —
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) PAR-27-098 Open
NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed) RFA-CA-27-007 Closed
NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed) RFA-CA-27-008 Closed
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) RFA-NS-27-007 Open
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional) PAR-25-324 Open
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) PAR-25-337 Open
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) PAR-25-338 Open
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) PA-25-304 Open
NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) PA-25-301 Open
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required) PA-25-306 Open
Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed) PAR-25-336 Open
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) PAR-25-346 Open
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) PAR-25-321 Open
Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) RFA-HG-25-007 Closed
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) PAR-25-298 Open
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) PAR-25-134 Open
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) PAR-25-171 Closed
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) PAR-25-107 Closed
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) PAR-25-106 Closed
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) PAR-25-148 Open
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed) PA-25-174 Closed
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed) PA-25-173 Closed
Show 40 more

Latest 50 listed here. See the rest on GovTribe.

Grant awards

Latest 10 of 18,287 listed here. See the rest on GovTribe.

Top recipients by federal obligations

Rank Recipient Federal obligations Share
1 Public Health Institute $1,091,691,391 4%
2 Dana-Farber Cancer Institute, Inc. $831,026,911 3%
3 The Univeristy Of Texas M.d. Anderson Cancer Center $768,811,311 3%
4 Icahn School Of Medicine At Mount Sinai $755,506,852 3%
5 Brigham & Womens Hospital Inc. $736,978,662 3%
6 Fred Hutchinson Cancer Center $651,367,252 2%
7 Mayo Clinic $590,552,711 2%
8 Sloan-Kettering Institute For Cancer Research $587,920,728 2%
9 The Johns Hopkins University $543,193,099 2%
10 NRG Oncology Foundation Inc. $521,646,656 2%

10 of 1,437 recipients listed here. See the rest on GovTribe.

Federal obligations by fiscal year

Fiscal year Federal obligations
FY2026 $1,271,874,556
FY2025 $2,219,208,883
FY2024 $3,124,942,338
FY2023 $3,415,936,272
FY2022 $2,858,445,223
FY2021 $1,984,387,999
FY2020 $932,696,615
FY2019 $853,683,772
FY2018 $923,130,589
FY2017 $817,200,297
FY2016 $793,299,888
FY2015 $784,512,655
FY2014 $777,729,921
FY2013 $701,224,239
FY2012 $733,354,076
FY2011 $736,212,840
FY2010 $757,889,459
FY2009 $736,267,115
FY2008 $380,958,685
FY2007 $549,849,160
FY2006 $672,469,235
FY2005 $609,108,204
FY2004 $662,683,752
FY2003 $616,668,263
FY2002 $557,013,765
FY2001 $281,456,322
Show all 26

Quick answers

What is Assistance Listing 93.395?

Assistance Listing 93.395 is Cancer Treatment Research, a federal grant program run by National Institutes of Health (Department of Health and Human Services).

What is the CFDA number for Cancer Treatment Research?

Its CFDA number is 93.395: Assistance Listing numbers were called CFDA numbers before 2018.

How much funding has Assistance Listing 93.395 awarded?

18,287 grant awards under 93.395 have obligated $28,262,839,486 in federal funds to 1,437 recipients.

Who receives the most funding from 93.395?

The recipients obligated the most under Cancer Treatment Research are Public Health Institute ($1,091,691,391), Dana-Farber Cancer Institute, Inc. ($831,026,911) and The Univeristy Of Texas M.d. Anderson Cancer Center ($768,811,311).

How much did 93.395 obligate in fiscal year 2025?

Grants under 93.395 obligated $2,219,208,883 in federal funds in fiscal year 2025.

Are there open grant opportunities under 93.395?

37 of the latest 50 opportunities under 93.395 are open or forecasted. The latest, Investigator-Focused Award (Parent R35), was posted on July 30, 2026.

On GovTribe

See this program's full record

  • Every grant award and opportunity under it
  • Funding by recipient, agency and assistance type
  • Alerts for new opportunities
  • Ask GovTribe AI about this program